Investor Relations Corporate ProfileAssembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral and liver diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates Assembly Biosciences Announces Upcoming Investor Conference Presentations Events & Presentations See all upcoming events Jun 8, 2026 at 8:40 AM EDT Goldman Sachs Global Conference Jun 3, 2026 at 4:20 PM EDT Jefferies 2026 Global Healthcare Conference - Fireside Chat May 27 - May 30, 2026 European Association for the Study of the Liver (EASL) Congress 2026 Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Investor Relations Corporate ProfileAssembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral and liver diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates Assembly Biosciences Announces Upcoming Investor Conference Presentations Events & Presentations See all upcoming events Jun 8, 2026 at 8:40 AM EDT Goldman Sachs Global Conference Jun 3, 2026 at 4:20 PM EDT Jefferies 2026 Global Healthcare Conference - Fireside Chat May 27 - May 30, 2026 European Association for the Study of the Liver (EASL) Congress 2026
